The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of combined melphalan percutaneous hepatic perfusion (M-PHP) and ipilimumab plus nivolumab (IPI+NIVO) in metastasized uveal melanoma (mUM): First results of the phase Ib part of the CHOPIN trial.
 
Thaïs M.L. Tong
No Relationships to Disclose
 
Mark C. Burgmans
Research Funding - Medtronic
 
Frank M. Speetjens
No Relationships to Disclose
 
Arian R. van Erkel
No Relationships to Disclose
 
Rutger W. van der Meer
No Relationships to Disclose
 
Carla S.P. van Rijswijk
Consulting or Advisory Role - Cook Medical (I)
Patents, Royalties, Other Intellectual Property - Cook Medical (I)
Travel, Accommodations, Expenses - Cook Medical (I)
 
Mare A. Jonker
No Relationships to Disclose
 
Inge C.F.M. Roozen
No Relationships to Disclose
 
Jacob Lutjeboer
No Relationships to Disclose
 
Els L. van Persijn-van Meerten
No Relationships to Disclose
 
Christian H. Martini
No Relationships to Disclose
 
Remco W.M. Zoethout
Consulting or Advisory Role - Delcath Systems
 
Fred G.J. Tijl
No Relationships to Disclose
 
Christian U. Blank
Stock and Other Ownership Interests - Immagene
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); GenMab (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche/Genentech (Inst); Third Rock Ventures
Research Funding - 4SC (Inst); Bristol-Myers Squibb (Inst); NanoString Technologies (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - WO 2021/177822 A1
Expert Testimony - Freshfields Bruckhaus Deringer
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Ellen Kapiteijn
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Delcath Systems (Inst); Ipsen (Inst); Lilly (Inst); Novartis (Inst); Pierre Fabre (Inst)
Research Funding - BMS (Inst); Pierre Fabre (Inst)